The estimated Net Worth of Igor Bilinsky is at least $299 Тысяча dollars as of 3 September 2024. Igor Bilinsky owns over 26,954 units of Oncternal Therapeutics stock worth over $275,531 and over the last 11 years he sold ONCT stock worth over $23,605. In addition, he makes $0 as Chief Business Officer at Oncternal Therapeutics.
Igor has made over 20 trades of the Oncternal Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 26,954 units of ONCT stock worth $111,994 on 3 September 2024.
The largest trade he's ever made was buying 90,000 units of Oncternal Therapeutics stock on 10 January 2014 worth over $127,800. On average, Igor trades about 6,683 units every 118 days since 2014. As of 3 September 2024 he still owns at least 66,313 units of Oncternal Therapeutics stock.
You can see the complete history of Igor Bilinsky stock trades at the bottom of the page.
Dr. Igor P. Bilinsky Ph.D. serves as Chief Business Officer of the Company. From January 2017 to January 2019, Dr. Bilinsky served as Chief Operating Officer of AmpliPhi Biosciences, a biotechnology company developing targeted therapies for patients with life-threatening bacterial infections. From September 2015 to January 2017, he was General Manager, Immuno-Oncology, and Senior Vice President, Special Operations and Research Operations, at Ignyta, a biotechnology company focused on precision medicine in oncology that was acquired by Roche. From October 2010 to September 2015, Dr. Bilinsky was Senior Vice President, Corporate Development at Vical. From 2007 to 2010 he was Vice President, Business Development and Special Operations at Halozyme Therapeutics, and from 2005 to 2007 he was Chief Executive Officer of Androclus Therapeutics. Dr. Bilinsky was previously a principal in the healthcare practice of Boston Consulting Group, where he advised companies in the biotechnology and pharmaceutical industries on business strategy, operational performance and mergers and acquisitions. Dr. Bilinsky received his B.S. in physics from the Moscow Institute of Physics and Technology and his Ph.D. in physics from the Massachusetts Institute of Technology.
Igor Bilinsky is 47, he's been the Chief Business Officer of Oncternal Therapeutics since 2019. There are 12 older and 3 younger executives at Oncternal Therapeutics. The oldest executive at Oncternal Therapeutics, Inc. is Michael Carter, 82, who is the Independent Director.
Igor's mailing address filed with the SEC is C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070.
Over the last 5 years, insiders at Oncternal Therapeutics have traded over $26,287 worth of Oncternal Therapeutics stock and bought 1,526,610 units worth $3,062,129 . The most active insiders traders include Pharmaceutical (Usa) Inc.Sh..., Charles Theuer и Robert James Wills. On average, Oncternal Therapeutics executives and independent directors trade stock every 68 days with the average trade being worth of $302,970. The most recent stock trade was executed by Robert James Wills on 8 April 2024, trading 3,086 units of ONCT stock currently worth $27,651.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California.
Oncternal Therapeutics executives and other stock owners filed with the SEC include: